DOCUMENT RESOURCES FOR EVERYONE
Documents tagged
New Strategies on Horizon Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong.
Documents New Strategies on Horizon Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong.

Slide 1New Strategies on Horizon Tony Mok MD Dept of Clinical Oncology The Chinse University of Hong Kong Slide 2 TKI is forever Addressing the difference Novel Target Slide…

Introduction Phosphatidylinositol 3 ′ -kinase (PIK3CA) encodes for a lipid kinase that regulates signaling pathways downstream of EGFR and is mutated in.
Documents Introduction Phosphatidylinositol 3 ′ -kinase (PIK3CA) encodes for a lipid kinase that regulates.....

Slide 1 Introduction Phosphatidylinositol 3 ′ -kinase (PIK3CA) encodes for a lipid kinase that regulates signaling pathways downstream of EGFR and is mutated in 10% to…

GICS 2012 Final skin toxicity and patient ‑ reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1 st ‑ line metastatic.
Documents GICS 2012 Final skin toxicity and patient ‑ reported outcomes results from PRIME: A randomized...

Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…

Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome Eric Van Cutsem*,
Documents Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF...

Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome Eric Van Cutsem*, I. Lang, G. Folprecht,…

Eric Van Cutsem*
Documents Eric Van Cutsem*

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience…

Carsten Bokemeyer*
Documents Carsten Bokemeyer*

KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten Bokemeyer* I Bondarenko,…

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Documents KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with...

KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten Bokemeyer* I Bondarenko,…

Introduction
Documents Introduction

Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…

Popular Categories
Relevant Tags